Funds advanced research to fast-track new treatments from the lab to clinical application.

The New Treatment Grant will provide funding to Australian researchers to:

• Carry out developed projects that will significantly accelerate treatments to a clinical stage for pancreatic cancer patients
• Contribute to advancing the translation of research from the lab to clinical studies or practice; accelerate the translation of promising therapies to clinical application
• Contribute to innovative projects that require resources to advance critical milestones
• Extend previous or existing work for a new treatment, scaling up existing research
• Grow capacity in pancreatic cancer research in Australia
• Improve survival from pancreatic cancer in line with our mission to triple survival by 2030

These projects should focus on more developed solutions that have the potential to move to clinical studies and make a significant impact on advancing the therapeutic field.

Criteria for funding

• Projects which are well developed, part of a larger program of work may be suited to this scheme
• Pilot or preliminary data should be developed and detailed as relevant to the application
• Where applications have multiple AI's, the role of each co-investigator must be outlined and justified
• Only one application per institution may be submitted for each scheme
• International collaborations are encouraged if the PI is located in Australia

Pankind will only fund projects where:

1. Only one application per institution may be submitted for each scheme.
2. The administering institution agrees to the terms and conditions of funding as outlined on this page and in Pankind's Research Funding Agreement. Please note amendments to the agreement terms are generally not accepted and institutional representatives must review the agreement prior to submission.  Please Note: The Funding Agreement is undergoing revisions. The current version will be available shortly. Until then, the previous version remains available for reference
3. The grant applicant (Principal Investigator) is based in Australia and the administering institution is an Australian organisation.
4. The applicant is named as Principal Investigator on no more than one application across all grant categories in the same round.
5. The applicant and all research team members are funded at a maximum of 1.0 full-time equivalent across the project.
6. Applicants who currently hold a Pankind grant as Principal Investigator must have that grant concluding within the current calendar year. Pankind reserves the right to alter or withdraw an offer of award where the requirements of a currently held grant have not been fulfilled.
7. Biotechnology, pharmaceutical, and other commercial entities are eligible to apply; however, Pankind reserves the right to vary the terms of funding for successful commercial applicants.
8. Adhere to the Permitted Use of Funds (see Policies and Procedures tab) within budgets.
9. Where the project involves human biospecimens or data, applicants must provide a letter of support from an appropriate and accessible repository or collection at the time of application. Ethics and governance arrangements must be clearly outlined, including the current status of approvals and a defined pathway to achieving any outstanding requirements before the project commences.

• Phone: (02) 7207 6970
• Email: info@pankind.org.au